CLP, OTCCNLF) has reported impressive interim data from its SCOPE cancer vaccine trial, prompting Panmure Liberum to upgrade its price target to 32p from 24p. The biotech company, which specialises in therapeutic cancer vaccines, reported significantly improved response rates from the SCOPE trial involving 47 patients across three cohorts, substantially outperforming current standard treatments. 